NB.1.8.1
SARS-CoV-2 NB.1.8.1 Variant
NB.1.8.1 is a rapidly spreading descendant of XDV.1.5.1 with enhanced transmissibility mutations affecting ACE2 binding and antibody evasion.
Quick Facts
Transmissibility
Enhanced transmissibility with ACE2 binding affinity improvements
Vaccine Evasion
Moderate immune evasion with class 1/4 antibody resistance
Global Prevalence
Rapidly spreading globally (10.7% of sequences by May 2025)
Symptoms & Signs
Common Symptoms
Distinctive Features
Prevention & Treatment
Prevention Strategies
Treatment Options
Current antivirals including Paxlovid and Remdesivir remain effective
Key Mutations
T22NF59SG184SA435SV445HT478IGlobal Surveillance
Key Research Findings
Significant increase from 2.5% to 10.7% of global sequences in 4 weeks
Enhanced ACE2 binding affinity due to V445H mutation
Modest reduction in neutralization potency of certain antibody classes
First detected in January 2025, spreading across multiple continents
High-Risk Groups
Related Variants
Omicron BA.5
BA.5 was the dominant Omicron subvariant during summer 2022, characterized by increased transmissibi...
Omicron XBB
XBB is a recombinant variant combining genetic material from two BA.2 sublineages, showing enhanced ...
JN.1
JN.1 emerged as a descendant of BA.2.86 with additional mutations conferring transmission advantages...
Medical Disclaimer
This information is for educational purposes only and should not replace professional medical advice. Always consult with qualified healthcare providers for diagnosis, treatment, and medical guidance. Information last updated: 2025-06-22.